Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)

NCT ID: NCT01930214

Last Updated: 2023-07-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 350 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-09-26
• Study Completion Date: 2017-06-01

Brief Summary

The objective of this study is to assess the current standard of care treatment outcome in none/mild, moderate and severely calcified coronary lesions using:

• A composite of MACE at 30-day and one (1) year post procedure, and
• Procedural and lesion success

Detailed Description

This prospective, non-randomized, multi-center study includes subjects who meet all of the inclusion and none of the exclusion criteria and sign the ICF. This study may treat up to approximately 500 subjects at up to 50 active sites in the U.S. Subjects may be followed up to three (3) years. Subjects will be stratified into one (1) of three (3) arms based on the degree of calcification in the coronary lesion as defined by this protocol. The duration of the study is expected to be approximately four (4) years.

Conditions

Coronary Artery Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

None/mild calcification

Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.

Percutaneous Coronary Intervention

Intervention Type: DEVICE

Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Moderate Calcification

Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.

Percutaneous Coronary Intervention

Intervention Type: DEVICE

Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Severe calcification

Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.

Percutaneous Coronary Intervention

Intervention Type: DEVICE

Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Interventions

Percutaneous Coronary Intervention

Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subjects must be at least 18 years of age.

2. Subjects must be scheduled for percutaneous coronary revascularization involving stent deployment in de novo coronary lesions. Percutaneous coronary revascularization is defined as treatment with commercially available devices that may include but not limited to balloon angioplasty, cutting balloon, rotablation, etc. followed by the stent placement.

3. Subjects CK-MB must be less than or equal to the upper limit of lab normal value within eight (8) hours prior to procedure. If CK-MB results are not yet available prior to initiating procedure, subjects Troponin I or Troponin T must be less than or equal to the upper limit of lab normal value within eight (8) hours prior to the procedure.

4. The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure.

5. The target vessel must be a native coronary artery with:

1. A stenosis ≥ 70% and < 100%, or

2. A stenosis ≥ 50% < 70% with evidence of clinical ischemia

6. The target vessel reference diameter must be ≥ 2.5mm and ≤ 4.0 mm.

7. The lesion length must not exceed 40 mm.

8. The target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow three (3) at baseline.

Exclusion Criteria

1. Inability to understand the study or a history of non-compliance with medical advice.

2. Unwilling or unable to sign the MACE clinical study ICF.

3. History of any cognitive or mental health status that would interfere with study participation.

4. Currently enrolled in any other pre-approval investigational study. This does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.).

5. Female subjects who are pregnant or planning to become pregnant within the study period.

6. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications.

7. Known sensitivity to contrast media, which cannot be adequately pre-medicated.

8. Diagnosed with chronic renal failure unless under hemodialysis, or has a serum creatinine level >2.5 mg/dl.

9. History of major cardiac intervention within 30-day, not including a PCI procedure for a staging purpose.

10. Evidence of heart failure by one of the following:

i. Left Ventricular Ejection Fraction (LVEF) ≤ 25% ii. New York Heart Association (NYHA) class III or IV iii. Clinical symptoms

11. History of a stroke or transient ischemic attack (TIA) within six (6) months

12. Active peptic ulcer or upper gastrointestinal (GI) bleeding within six (6) months.

13. History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.

14. Concurrent medical condition with a life expectancy of < 36 months.

15. History of immune deficiency.

16. Uncontrolled insulin dependent diabetes.

17. Evidence of active infections on the day of the index procedure.

18. Subject has planned cardiovascular intervention within 60 days post index procedure.

19. Subject with angiographically confirmed evidence of more than two (2) lesions within one (1) vessel or more than one (1) vessel requiring intervention, unless the treatment is staged. See Section 10.1 for more details.

20. Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or Left Internal Mammary Artery/ Right Internal Mammary Artery (LIMA/RIMA) bypass.

21. Target vessel has angiographically visible or suspected thrombus.

22. Target vessel appears to be/is excessively tortuous at baseline.

23. Target lesion is an ostial location (within 5mm of ostium) or an unprotected left main lesion.

24. Target lesion is a bifurcation (side branch ≥ 1.5mm).

25. Treatment of the target lesion with the CSI coronary Diamondback Orbital Atherectomy System (OAS).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Medical Devices

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Samin K Sharma, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Arkansas Heart Hospital

Little Rock, Arkansas, United States

Glendale Adventist Medical Center

Glendale, California, United States

Hartford Hospital

Hartford, Connecticut, United States

MedStar Washington Hospital

Washington D.C., District of Columbia, United States

Clearwater Cardiovascular & Interventional Consultants

Clearwater, Florida, United States

Mount Sinai Medical Center Heart Institute

Miami Beach, Florida, United States

Cardiovascular Institute of NW Florida

Panama City, Florida, United States

Georgia Regents Research Institute

Augusta, Georgia, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Prairie Education & Research Cooperative

Springfield, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

John Hopkins

Baltimore, Maryland, United States

Tufts Medical Center

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Baystate Medical Center

Springfield, Massachusetts, United States

McLaren Bay Regional

Bay City, Michigan, United States

Beaumont Hospital

Royal Oak, Michigan, United States

Boone Hospital

Columbia, Missouri, United States

Saint Luke's

Kansas City, Missouri, United States

Barnes Jewish Hospital

St Louis, Missouri, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Jersey Shore Medical Center

Neptune City, New Jersey, United States

Mount Sinai New York

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

East Carolina University

Greenville, North Carolina, United States

North Carolina Heart & Vascular Specialists

Raleigh, North Carolina, United States

OhioHealth Research Institute

Columbus, Ohio, United States

St. John Health System

Tulsa, Oklahoma, United States

University Pittsburg MC - Hamot

Erie, Pennsylvania, United States

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

University of Tennessee

Memphis, Tennessee, United States

Houston Methodist Research Institute

Houston, Texas, United States

Mission Research Institute

New Braunfels, Texas, United States

Providence Health Center

Waco, Texas, United States

Countries

United States

References

Sharma SK, Bolduan RW, Patel MR, Martinsen BJ, Azemi T, Giugliano G, Resar JR, Mehran R, Cohen DJ, Popma JJ, Waksman R. Impact of calcification on percutaneous coronary intervention: MACE-Trial 1-year results. Catheter Cardiovasc Interv. 2019 Aug 1;94(2):187-194. doi: 10.1002/ccd.28099. Epub 2019 Jan 25.

Reference Type: RESULT

PMID: 30681262 (View on PubMed)

Other Identifiers

CLN-0002-P

Identifier Type: -

Identifier Source: org_study_id